| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | 0.011 | 0.9 |
| mRNA | Platin | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.9 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | -0.0071 | 0.9 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | VER-155008 | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |